These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

351 related items for PubMed ID: 27927041

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Drug discovery and development for Huntington's disease - an orphan indication with high medical need.
    Heitz F, La Rosa S, Gonzalez-Couto E, Gaviraghi G, Terstappen GC.
    IDrugs; 2008 Sep; 11(9):653-60. PubMed ID: 18763216
    [Abstract] [Full Text] [Related]

  • 3. Investigational drugs for the management of Huntington's disease: are we there yet?
    Kulkarni P, Saxena U.
    Expert Opin Investig Drugs; 2014 Dec; 23(12):1595-603. PubMed ID: 25084527
    [Abstract] [Full Text] [Related]

  • 4. Xyloketal-derived small molecules show protective effect by decreasing mutant Huntingtin protein aggregates in Caenorhabditis elegans model of Huntington's disease.
    Zeng Y, Guo W, Xu G, Wang Q, Feng L, Long S, Liang F, Huang Y, Lu X, Li S, Zhou J, Burgunder JM, Pang J, Pei Z.
    Drug Des Devel Ther; 2016 Dec; 10():1443-51. PubMed ID: 27110099
    [Abstract] [Full Text] [Related]

  • 5. Huntington's disease: prospects for neuroprotective therapy 10 years after the discovery of the causative genetic mutation.
    Hersch SM.
    Curr Opin Neurol; 2003 Aug; 16(4):501-6. PubMed ID: 12869810
    [Abstract] [Full Text] [Related]

  • 6. Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis.
    Dunkel P, Chai CL, Sperlágh B, Huleatt PB, Mátyus P.
    Expert Opin Investig Drugs; 2012 Sep; 21(9):1267-308. PubMed ID: 22741814
    [Abstract] [Full Text] [Related]

  • 7. Targeting mutant huntingtin for the development of disease-modifying therapy.
    Appl T, Kaltenbach L, Lo DC, Terstappen GC.
    Drug Discov Today; 2012 Nov; 17(21-22):1217-23. PubMed ID: 22772050
    [Abstract] [Full Text] [Related]

  • 8. Huntington's disease: progress and potential in the field.
    Stack EC, Ferrante RJ.
    Expert Opin Investig Drugs; 2007 Dec; 16(12):1933-53. PubMed ID: 18042002
    [Abstract] [Full Text] [Related]

  • 9. Huntington's disease: novel therapeutic perspectives hanging in the balance.
    Saavedra A, García-Díaz Barriga G, Pérez-Navarro E, Alberch J.
    Expert Opin Ther Targets; 2018 May; 22(5):385-399. PubMed ID: 29671352
    [Abstract] [Full Text] [Related]

  • 10. Emerging drug therapies in Huntington's disease.
    Mason SL, Barker RA.
    Expert Opin Emerg Drugs; 2009 Jun; 14(2):273-97. PubMed ID: 19453283
    [Abstract] [Full Text] [Related]

  • 11. Emerging pharmacological approaches for Huntington's disease.
    Singh K, Jain D, Sethi P, Gupta JK, Tripathi AK, Kumar S, Sarker SD, Nahar L, Guru A.
    Eur J Pharmacol; 2024 Oct 05; 980():176873. PubMed ID: 39117264
    [Abstract] [Full Text] [Related]

  • 12. Questions swirl around failures of disease-modifying Huntington's drugs.
    Sheridan C.
    Nat Biotechnol; 2021 Jun 05; 39(6):650-652. PubMed ID: 34113039
    [No Abstract] [Full Text] [Related]

  • 13. Emerging chemotherapeutic strategies for Huntington's disease.
    Ryu H, Ferrante RJ.
    Expert Opin Emerg Drugs; 2005 May 05; 10(2):345-63. PubMed ID: 15934871
    [Abstract] [Full Text] [Related]

  • 14. Therapeutic Update on Huntington's Disease: Symptomatic Treatments and Emerging Disease-Modifying Therapies.
    Dash D, Mestre TA.
    Neurotherapeutics; 2020 Oct 05; 17(4):1645-1659. PubMed ID: 32705582
    [Abstract] [Full Text] [Related]

  • 15. Pridopidine for the treatment of Huntington's disease.
    Shannon KM.
    Expert Opin Investig Drugs; 2016 Oct 05; 25(4):485-92. PubMed ID: 26881734
    [Abstract] [Full Text] [Related]

  • 16. Society for Neuroscience--38th Annual Meeting--Focus on Huntington's disease.
    Gotham S.
    IDrugs; 2009 Jan 05; 12(1):12-3. PubMed ID: 19127497
    [No Abstract] [Full Text] [Related]

  • 17. [Regulation of cholesterol metabolism is neuroprotective in Huntington's disease].
    Caboche J, Kacher R, Betuing S.
    Med Sci (Paris); 2020 Jan 05; 36(1):12-15. PubMed ID: 32014090
    [No Abstract] [Full Text] [Related]

  • 18. Epigenetic modifications as novel therapeutic targets for Huntington's disease.
    Wang F, Fischhaber PL, Guo C, Tang TS.
    Epigenomics; 2014 Jun 05; 6(3):287-97. PubMed ID: 25111483
    [Abstract] [Full Text] [Related]

  • 19. Recent advances in Huntington's disease.
    Gutekunst CA, Norflus F, Hersch SM.
    Curr Opin Neurol; 2000 Aug 05; 13(4):445-50. PubMed ID: 10970063
    [Abstract] [Full Text] [Related]

  • 20. Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat.
    Clemens LE, Weber JJ, Wlodkowski TT, Yu-Taeger L, Michaud M, Calaminus C, Eckert SH, Gaca J, Weiss A, Magg JC, Jansson EK, Eckert GP, Pichler BJ, Bordet T, Pruss RM, Riess O, Nguyen HP.
    Brain; 2015 Dec 05; 138(Pt 12):3632-53. PubMed ID: 26490331
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.